# Nectar Lifesciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nectar-lifesciences-2

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.nectarlifesciences.com
- Total disclosed funding: $8M
- Latest round: Seed (Mar 17, 2022)
- Investors on record: 2

## About

Based in the US, and founded in 2021, Nectar Lifesciences offers a comprehensive, vertically integrated allergy healthcare platform by leveraging data and clinical research. In March 2022, Nectar Lifesciences raised USD 8 million in seed funding co-led by new investors Juxtapose and Obvious Ventures.

The company uses data and clinical research to offer a personalized approach to allergy care.

The company plans to use the seed funds to continue developing proprietary and personalized allergy solutions ahead of the nationwide launch of Nectar in the coming months.

## Funding rounds

- Seed, Mar 17, 2022, $8M — Obvious, Juxtapose

## Investors

- Obvious (https://capitalatlas.ai/funds/obvious) — Seed
- Juxtapose (https://capitalatlas.ai/funds/juxtapose) — Seed